Dapivirine

Chemical compound
  • G01AX17 (WHO)
Identifiers
  • 4-{[4-(Mesitylamino)-2-pyrimidinyl]amino}benzonitrile
CAS Number
  • 244767-67-7
PubChem CID
  • 214347
DrugBank
  • DB08639
ChemSpider
  • 185837
UNII
  • TCN4MG2VXS
KEGG
  • D11246
ChEMBL
  • ChEMBL70663
CompTox Dashboard (EPA)
  • DTXSID40179244 Edit this at Wikidata
ECHA InfoCard100.214.755 Edit this at WikidataChemical and physical dataFormulaC20H19N5Molar mass329.3983D model (JSmol)
  • Interactive image
  • Cc1cc(c(c(c1)C)Nc2ccnc(n2)Nc3ccc(cc3)C#N)C
InChI
  • InChI=1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25)
  • Key:ILAYIAGXTHKHNT-UHFFFAOYSA-N

Dapivirine is a non-nucleoside reverse transcriptase inhibitor developed at Janssen Therapeutics (formerly Tibotec Therapeutics).[1] The International Partnership for Microbicides has held exclusive worldwide rights to dapivirine since 2014,[2] building upon a 2004 royalty-free license to develop dapivirine-based microbicides for women in resource-poor countries.[3]

A monthly intravaginal ring containing dapivirine has been developed as a way of preventing infection by human immunodeficiency virus in women. Two phase 3 clinical trials of intravaginal dapivirine rings for HIV prevention were completed in 2015 and results were announced at the 2016 Conference on Retroviruses and Opportunistic Infections. The ASPIRE Study (MTN-020) reported a 27% reduction in HIV-1 acquisition (95% CI 12-57%, p=0.007), with a trend toward greater protection in women over age 21 and no significant protection for women under age 21.[4] The Ring Study (IPM-027) reported a 31% reduction in HIV acquisition (95% CI 0.9-51.5%, p=0.040) also with a trend toward greater efficacy in women over age 21.[5] In both trials, more than 80% of returned rings showed signs of drug depletion indicating at least some use, and more than 80% of blood samples from participants in the active arm had levels of dapivirine consistent at least 8 hours of continuous use preceding the blood test. Neither trial could evaluate whether the product was used consistently between study visits.

As of December 2019, it became the first of its kind to be submitted for regulatory approval.[6][7]

External links

  • Dapivirine Vaginal Ring at PrEPWatch.org

References

  1. ^ "Johnson & Johnson to Acquire Tibotec-Virco (NYSE:JNJ)". www.investor.jnj.com. Archived from the original on 2016-05-08. Retrieved 2016-04-13.
  2. ^ hseltzer (8 May 2014). "IPM Receives Worldwide Rights to HIV Prevention Medicine". www.ipmglobal.org. Retrieved 2016-04-13.
  3. ^ ipm-admin (29 September 2010). "Dapivirine (TMC120)". www.ipmglobal.org. Retrieved 2016-04-13.
  4. ^ Baeten JM. "A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women". Retrieved 2016-04-13.
  5. ^ Nel A. "Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women". Retrieved 2016-04-13.
  6. ^ PrEWatch.org. "Nextgen-Dapivirine Vaginal Ring". Retrieved 2020-05-26.
  7. ^ ipmglobal.org (3 March 2016). "Dapivirine Ring". Retrieved 2020-05-26.
  • v
  • t
  • e
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitorsEntry/fusion inhibitors
(Discovery and development)Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))Maturation inhibitorsProtease Inhibitors (PI)
(Discovery and development)
1st generation
2nd generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1st generation
2nd generation
Combined formulations
Pharmacokinetic boostersExperimental agents
Uncoating inhibitors
Transcription inhibitors
  • Tat antagonists
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. ◊Formerly or rarely used agent.


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e